PMC:7200337 / 44425-46163 JSON TXT

Annnotations TAB JSON ListView MergeView

2_test

{"project":"2_test","denotations":[{"id":"32505227-15606632-46575340","span":{"begin":47,"end":51},"obj":"15606632"},{"id":"32505227-32213337-46575341","span":{"begin":527,"end":531},"obj":"32213337"},{"id":"32505227-32213337-46575342","span":{"begin":853,"end":857},"obj":"32213337"},{"id":"T91196","span":{"begin":47,"end":51},"obj":"15606632"},{"id":"T89937","span":{"begin":527,"end":531},"obj":"32213337"},{"id":"T38281","span":{"begin":853,"end":857},"obj":"32213337"}],"text":"Similar to SARS-CoV-1 infection (Hsueh et al., 2004), seroconversion occurs in most COVID-19 patients between 7 and 14 days after the onset of symptoms, and antibody titers persist in the weeks following virus clearance (Figure 4 ) (Haveri et al., 2020, Lou et al., 2020, Okba et al., 2020, Tan et al., 2020b, Wölfel et al., 2020, Wu et al., 2020b, Zhao et al., 2020a). Antibodies binding the SARS-CoV-2 internal N protein and the external S glycoprotein are commonly detected (Amanat et al., 2020, Ju et al., 2020, To et al., 2020). The receptor binding domain (RBD) of the S protein is highly immunogenic, and antibodies binding this domain can be potently neutralizing, blocking virus interactions with the host entry receptor, ACE2 (Ju et al., 2020, Wu et al., 2020b). Anti-RBD nAbs are detected in most tested patients (Ju et al., 2020, To et al., 2020, Wu et al., 2020b). Although crossreactivity to SARS-CoV-1 S and N proteins and to MERS-CoV S protein was detected in plasma from COVID-19 patients, no crossreactivity was found to the RBD from SARS-CoV-1 or MERS-CoV. In addition, plasma from COVID-19 patients did not neutralize SARS-CoV-1 or MERS-CoV (Ju et al., 2020).\nFigure 4 Antibody-Mediated Immunity in SARS-CoV-2\nVirus-specific IgM and IgG are detectable in serum between 7 and 14 days after the onset of symptoms. Viral RNA is inversely correlated with neutralizing antibody titers. Higher titers have been observed in critically ill patients, but it is unknown whether antibody responses somehow contribute to pulmonary pathology. The SARS-CoV-1 humoral response is relatively short lived, and memory B cells may disappear altogether, suggesting that immunity with SARS-CoV-2 may wane 1–2 years after primary infection."}

LitCovid-PD-FMA-UBERON

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T50","span":{"begin":1275,"end":1280},"obj":"Body_part"}],"attributes":[{"id":"A50","pred":"uberon_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Similar to SARS-CoV-1 infection (Hsueh et al., 2004), seroconversion occurs in most COVID-19 patients between 7 and 14 days after the onset of symptoms, and antibody titers persist in the weeks following virus clearance (Figure 4 ) (Haveri et al., 2020, Lou et al., 2020, Okba et al., 2020, Tan et al., 2020b, Wölfel et al., 2020, Wu et al., 2020b, Zhao et al., 2020a). Antibodies binding the SARS-CoV-2 internal N protein and the external S glycoprotein are commonly detected (Amanat et al., 2020, Ju et al., 2020, To et al., 2020). The receptor binding domain (RBD) of the S protein is highly immunogenic, and antibodies binding this domain can be potently neutralizing, blocking virus interactions with the host entry receptor, ACE2 (Ju et al., 2020, Wu et al., 2020b). Anti-RBD nAbs are detected in most tested patients (Ju et al., 2020, To et al., 2020, Wu et al., 2020b). Although crossreactivity to SARS-CoV-1 S and N proteins and to MERS-CoV S protein was detected in plasma from COVID-19 patients, no crossreactivity was found to the RBD from SARS-CoV-1 or MERS-CoV. In addition, plasma from COVID-19 patients did not neutralize SARS-CoV-1 or MERS-CoV (Ju et al., 2020).\nFigure 4 Antibody-Mediated Immunity in SARS-CoV-2\nVirus-specific IgM and IgG are detectable in serum between 7 and 14 days after the onset of symptoms. Viral RNA is inversely correlated with neutralizing antibody titers. Higher titers have been observed in critically ill patients, but it is unknown whether antibody responses somehow contribute to pulmonary pathology. The SARS-CoV-1 humoral response is relatively short lived, and memory B cells may disappear altogether, suggesting that immunity with SARS-CoV-2 may wane 1–2 years after primary infection."}

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T280","span":{"begin":11,"end":19},"obj":"Disease"},{"id":"T281","span":{"begin":22,"end":31},"obj":"Disease"},{"id":"T282","span":{"begin":84,"end":92},"obj":"Disease"},{"id":"T283","span":{"begin":393,"end":401},"obj":"Disease"},{"id":"T284","span":{"begin":906,"end":914},"obj":"Disease"},{"id":"T285","span":{"begin":988,"end":996},"obj":"Disease"},{"id":"T286","span":{"begin":1052,"end":1060},"obj":"Disease"},{"id":"T287","span":{"begin":1101,"end":1109},"obj":"Disease"},{"id":"T288","span":{"begin":1138,"end":1146},"obj":"Disease"},{"id":"T289","span":{"begin":1219,"end":1227},"obj":"Disease"},{"id":"T290","span":{"begin":1554,"end":1562},"obj":"Disease"},{"id":"T291","span":{"begin":1684,"end":1692},"obj":"Disease"},{"id":"T292","span":{"begin":1728,"end":1737},"obj":"Disease"}],"attributes":[{"id":"A280","pred":"mondo_id","subj":"T280","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A281","pred":"mondo_id","subj":"T281","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A282","pred":"mondo_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A283","pred":"mondo_id","subj":"T283","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A284","pred":"mondo_id","subj":"T284","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A285","pred":"mondo_id","subj":"T285","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A286","pred":"mondo_id","subj":"T286","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A287","pred":"mondo_id","subj":"T287","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A288","pred":"mondo_id","subj":"T288","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A289","pred":"mondo_id","subj":"T289","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A290","pred":"mondo_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A291","pred":"mondo_id","subj":"T291","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A292","pred":"mondo_id","subj":"T292","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Similar to SARS-CoV-1 infection (Hsueh et al., 2004), seroconversion occurs in most COVID-19 patients between 7 and 14 days after the onset of symptoms, and antibody titers persist in the weeks following virus clearance (Figure 4 ) (Haveri et al., 2020, Lou et al., 2020, Okba et al., 2020, Tan et al., 2020b, Wölfel et al., 2020, Wu et al., 2020b, Zhao et al., 2020a). Antibodies binding the SARS-CoV-2 internal N protein and the external S glycoprotein are commonly detected (Amanat et al., 2020, Ju et al., 2020, To et al., 2020). The receptor binding domain (RBD) of the S protein is highly immunogenic, and antibodies binding this domain can be potently neutralizing, blocking virus interactions with the host entry receptor, ACE2 (Ju et al., 2020, Wu et al., 2020b). Anti-RBD nAbs are detected in most tested patients (Ju et al., 2020, To et al., 2020, Wu et al., 2020b). Although crossreactivity to SARS-CoV-1 S and N proteins and to MERS-CoV S protein was detected in plasma from COVID-19 patients, no crossreactivity was found to the RBD from SARS-CoV-1 or MERS-CoV. In addition, plasma from COVID-19 patients did not neutralize SARS-CoV-1 or MERS-CoV (Ju et al., 2020).\nFigure 4 Antibody-Mediated Immunity in SARS-CoV-2\nVirus-specific IgM and IgG are detectable in serum between 7 and 14 days after the onset of symptoms. Viral RNA is inversely correlated with neutralizing antibody titers. Higher titers have been observed in critically ill patients, but it is unknown whether antibody responses somehow contribute to pulmonary pathology. The SARS-CoV-1 humoral response is relatively short lived, and memory B cells may disappear altogether, suggesting that immunity with SARS-CoV-2 may wane 1–2 years after primary infection."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T571","span":{"begin":204,"end":209},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T572","span":{"begin":682,"end":687},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T573","span":{"begin":808,"end":814},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T574","span":{"begin":976,"end":982},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T575","span":{"begin":1089,"end":1095},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T576","span":{"begin":1230,"end":1235},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T577","span":{"begin":1620,"end":1627},"obj":"http://purl.obolibrary.org/obo/CL_0000236"}],"text":"Similar to SARS-CoV-1 infection (Hsueh et al., 2004), seroconversion occurs in most COVID-19 patients between 7 and 14 days after the onset of symptoms, and antibody titers persist in the weeks following virus clearance (Figure 4 ) (Haveri et al., 2020, Lou et al., 2020, Okba et al., 2020, Tan et al., 2020b, Wölfel et al., 2020, Wu et al., 2020b, Zhao et al., 2020a). Antibodies binding the SARS-CoV-2 internal N protein and the external S glycoprotein are commonly detected (Amanat et al., 2020, Ju et al., 2020, To et al., 2020). The receptor binding domain (RBD) of the S protein is highly immunogenic, and antibodies binding this domain can be potently neutralizing, blocking virus interactions with the host entry receptor, ACE2 (Ju et al., 2020, Wu et al., 2020b). Anti-RBD nAbs are detected in most tested patients (Ju et al., 2020, To et al., 2020, Wu et al., 2020b). Although crossreactivity to SARS-CoV-1 S and N proteins and to MERS-CoV S protein was detected in plasma from COVID-19 patients, no crossreactivity was found to the RBD from SARS-CoV-1 or MERS-CoV. In addition, plasma from COVID-19 patients did not neutralize SARS-CoV-1 or MERS-CoV (Ju et al., 2020).\nFigure 4 Antibody-Mediated Immunity in SARS-CoV-2\nVirus-specific IgM and IgG are detectable in serum between 7 and 14 days after the onset of symptoms. Viral RNA is inversely correlated with neutralizing antibody titers. Higher titers have been observed in critically ill patients, but it is unknown whether antibody responses somehow contribute to pulmonary pathology. The SARS-CoV-1 humoral response is relatively short lived, and memory B cells may disappear altogether, suggesting that immunity with SARS-CoV-2 may wane 1–2 years after primary infection."}

LitCovid-PD-CHEBI

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T230","span":{"begin":415,"end":422},"obj":"Chemical"},{"id":"T231","span":{"begin":442,"end":454},"obj":"Chemical"},{"id":"T232","span":{"begin":577,"end":584},"obj":"Chemical"},{"id":"T233","span":{"begin":925,"end":933},"obj":"Chemical"},{"id":"T234","span":{"begin":952,"end":959},"obj":"Chemical"}],"attributes":[{"id":"A230","pred":"chebi_id","subj":"T230","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A231","pred":"chebi_id","subj":"T231","obj":"http://purl.obolibrary.org/obo/CHEBI_17089"},{"id":"A232","pred":"chebi_id","subj":"T232","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A233","pred":"chebi_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A234","pred":"chebi_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"Similar to SARS-CoV-1 infection (Hsueh et al., 2004), seroconversion occurs in most COVID-19 patients between 7 and 14 days after the onset of symptoms, and antibody titers persist in the weeks following virus clearance (Figure 4 ) (Haveri et al., 2020, Lou et al., 2020, Okba et al., 2020, Tan et al., 2020b, Wölfel et al., 2020, Wu et al., 2020b, Zhao et al., 2020a). Antibodies binding the SARS-CoV-2 internal N protein and the external S glycoprotein are commonly detected (Amanat et al., 2020, Ju et al., 2020, To et al., 2020). The receptor binding domain (RBD) of the S protein is highly immunogenic, and antibodies binding this domain can be potently neutralizing, blocking virus interactions with the host entry receptor, ACE2 (Ju et al., 2020, Wu et al., 2020b). Anti-RBD nAbs are detected in most tested patients (Ju et al., 2020, To et al., 2020, Wu et al., 2020b). Although crossreactivity to SARS-CoV-1 S and N proteins and to MERS-CoV S protein was detected in plasma from COVID-19 patients, no crossreactivity was found to the RBD from SARS-CoV-1 or MERS-CoV. In addition, plasma from COVID-19 patients did not neutralize SARS-CoV-1 or MERS-CoV (Ju et al., 2020).\nFigure 4 Antibody-Mediated Immunity in SARS-CoV-2\nVirus-specific IgM and IgG are detectable in serum between 7 and 14 days after the onset of symptoms. Viral RNA is inversely correlated with neutralizing antibody titers. Higher titers have been observed in critically ill patients, but it is unknown whether antibody responses somehow contribute to pulmonary pathology. The SARS-CoV-1 humoral response is relatively short lived, and memory B cells may disappear altogether, suggesting that immunity with SARS-CoV-2 may wane 1–2 years after primary infection."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T143","span":{"begin":688,"end":714},"obj":"http://purl.obolibrary.org/obo/GO_0051701"},{"id":"T144","span":{"begin":1613,"end":1619},"obj":"http://purl.obolibrary.org/obo/GO_0007613"}],"text":"Similar to SARS-CoV-1 infection (Hsueh et al., 2004), seroconversion occurs in most COVID-19 patients between 7 and 14 days after the onset of symptoms, and antibody titers persist in the weeks following virus clearance (Figure 4 ) (Haveri et al., 2020, Lou et al., 2020, Okba et al., 2020, Tan et al., 2020b, Wölfel et al., 2020, Wu et al., 2020b, Zhao et al., 2020a). Antibodies binding the SARS-CoV-2 internal N protein and the external S glycoprotein are commonly detected (Amanat et al., 2020, Ju et al., 2020, To et al., 2020). The receptor binding domain (RBD) of the S protein is highly immunogenic, and antibodies binding this domain can be potently neutralizing, blocking virus interactions with the host entry receptor, ACE2 (Ju et al., 2020, Wu et al., 2020b). Anti-RBD nAbs are detected in most tested patients (Ju et al., 2020, To et al., 2020, Wu et al., 2020b). Although crossreactivity to SARS-CoV-1 S and N proteins and to MERS-CoV S protein was detected in plasma from COVID-19 patients, no crossreactivity was found to the RBD from SARS-CoV-1 or MERS-CoV. In addition, plasma from COVID-19 patients did not neutralize SARS-CoV-1 or MERS-CoV (Ju et al., 2020).\nFigure 4 Antibody-Mediated Immunity in SARS-CoV-2\nVirus-specific IgM and IgG are detectable in serum between 7 and 14 days after the onset of symptoms. Viral RNA is inversely correlated with neutralizing antibody titers. Higher titers have been observed in critically ill patients, but it is unknown whether antibody responses somehow contribute to pulmonary pathology. The SARS-CoV-1 humoral response is relatively short lived, and memory B cells may disappear altogether, suggesting that immunity with SARS-CoV-2 may wane 1–2 years after primary infection."}

LitCovid-PubTator

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T239","span":{"begin":0,"end":369},"obj":"Sentence"},{"id":"T240","span":{"begin":370,"end":533},"obj":"Sentence"},{"id":"T241","span":{"begin":534,"end":772},"obj":"Sentence"},{"id":"T242","span":{"begin":773,"end":877},"obj":"Sentence"},{"id":"T243","span":{"begin":878,"end":1075},"obj":"Sentence"},{"id":"T244","span":{"begin":1076,"end":1179},"obj":"Sentence"},{"id":"T245","span":{"begin":1180,"end":1229},"obj":"Sentence"},{"id":"T246","span":{"begin":1230,"end":1331},"obj":"Sentence"},{"id":"T247","span":{"begin":1332,"end":1400},"obj":"Sentence"},{"id":"T248","span":{"begin":1401,"end":1549},"obj":"Sentence"},{"id":"T249","span":{"begin":1550,"end":1738},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Similar to SARS-CoV-1 infection (Hsueh et al., 2004), seroconversion occurs in most COVID-19 patients between 7 and 14 days after the onset of symptoms, and antibody titers persist in the weeks following virus clearance (Figure 4 ) (Haveri et al., 2020, Lou et al., 2020, Okba et al., 2020, Tan et al., 2020b, Wölfel et al., 2020, Wu et al., 2020b, Zhao et al., 2020a). Antibodies binding the SARS-CoV-2 internal N protein and the external S glycoprotein are commonly detected (Amanat et al., 2020, Ju et al., 2020, To et al., 2020). The receptor binding domain (RBD) of the S protein is highly immunogenic, and antibodies binding this domain can be potently neutralizing, blocking virus interactions with the host entry receptor, ACE2 (Ju et al., 2020, Wu et al., 2020b). Anti-RBD nAbs are detected in most tested patients (Ju et al., 2020, To et al., 2020, Wu et al., 2020b). Although crossreactivity to SARS-CoV-1 S and N proteins and to MERS-CoV S protein was detected in plasma from COVID-19 patients, no crossreactivity was found to the RBD from SARS-CoV-1 or MERS-CoV. In addition, plasma from COVID-19 patients did not neutralize SARS-CoV-1 or MERS-CoV (Ju et al., 2020).\nFigure 4 Antibody-Mediated Immunity in SARS-CoV-2\nVirus-specific IgM and IgG are detectable in serum between 7 and 14 days after the onset of symptoms. Viral RNA is inversely correlated with neutralizing antibody titers. Higher titers have been observed in critically ill patients, but it is unknown whether antibody responses somehow contribute to pulmonary pathology. The SARS-CoV-1 humoral response is relatively short lived, and memory B cells may disappear altogether, suggesting that immunity with SARS-CoV-2 may wane 1–2 years after primary infection."}

PMC:7200337 / 44425-46163 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7200337 / 44425-46163 JSON TXT